Guadalupe Lemus
Family · Porterville, CANPI 1962803692
Payments from drug & device makers
Across 263 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$996
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$714
- Lilly USA, LLC$637
- Boehringer Ingelheim$486
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,02599%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $1,161 |
| AbbVie | 45 | $1,125 |
| Novo Nordisk | 46 | $996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $714 |
| Lilly USA, LLC | 24 | $637 |
| Boehringer Ingelheim | 24 | $486 |
| Biohaven Pharmaceuticals, Inc. | 3 | $355 |
| Bayer | 12 | $242 |
| Ironwood Pharmaceuticals, Inc | 4 | $219 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $173 |
| Otsuka America Pharmaceutical, Inc. | 3 | $164 |
| Pfizer | 7 | $141 |
| Abbott | 1 | $137 |
| Amgen | 6 | $111 |
| Philips North America LLC | 3 | $61 |
| Sumitomo Pharma America, Inc. | 4 | $59 |
| Dexcom, Inc. | 2 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Agile Therapeutics, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 1 | $29 |
| Novartis | 2 | $29 |
| Pulmonx Corporation | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| GSK | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Exact Sciences | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,110 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 79 | $157,365 |
| OzempicSemaglutide | 96 | $91,727 |
| OtezlaApremilast | 15 | $71,567 |
| JardianceEmpagliflozin | 43 | $47,625 |
| JanuviaSitagliptin Phosphate | 34 | $33,889 |
| LinzessLinaclotide | 31 | $29,571 |
| FarxigaDapagliflozin Propanediol | 29 | $29,502 |
| GemtesaVibegron | 33 | $24,880 |
| MounjaroTirzepatide | 18 | $21,562 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,779 |
| EliquisApixaban | 14 | $13,350 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $9,609 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,475 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,128 |
| PremproEstrogen,con/M-Progest Acet | 15 | $3,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $996 | $249,092175 claims |
| AmgenOtezla | $111 | $71,56715 claims |
| Boehringer IngelheimJardiance | $486 | $47,62543 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,161 | $43,28152 claims |
| AbbVieLinzess | $1,125 | $29,57131 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $59 | $24,88033 claims |
| Lilly USA, LLCMounjaro | $637 | $21,56218 claims |
| PfizerEliquis, Prempro | $141 | $17,09329 claims |
| GSKAnoro Ellipta | $20 | $5,12812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Porterville
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.